Valuation: Nutriband Inc.

Market Cap 36.83M 32.23M 29.71M 27.53M 52.27M 3.5B 53.11M 356M 139M 1.73B 138M 135M 5.96B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 32.5M 28.44M 26.21M 24.3M 46.12M 3.08B 46.87M 314M 122M 1.52B 122M 119M 5.26B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day-3.50%
1 week-5.02%
Current month-5.02%
1 month-15.36%
3 months-24.25%
6 months-33.11%
Current year-33.26%
1 week 3
Extreme 3
3.31
1 month 2.9
Extreme 2.9
3.62
Current year 2.9
Extreme 2.9
4.98
1 year 2.9
Extreme 2.9
9.21
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.8571
43.54
Manager TitleAgeSince
Chief Executive Officer 35 2015-12-31
Chief Executive Officer 52 -
Director of Finance/CFO 77 2020-09-01
Director TitleAgeSince
Chairman 52 2022-01-20
Director/Board Member 48 2018-06-30
Director/Board Member 38 2018-06-30
Date Insider Type Main position Quantity % Market Cap.
25-01-30Option

Chief Financial Officer

212,837 1.9164%
25-01-30Other

Founder

126,833 1.1420%
24-03-19Free

Founder

75,000 0.9575%
Change 5-day change 1-year change 3-year change Capi.($)
-3.50%-5.02%-64.23%-7.06% 38.17M
+0.22%+5.62%-28.32%-9.88% 167B
+0.93%+7.16%-4.38%-2.40% 106B
+1.99%+7.60%+0.65%+59.53% 58.09B
-3.43%-4.53%+49.74%+51.85% 52.7B
+0.49%+3.28%-9.63%-39.16% 42.86B
+0.61%+9.05% - - 36.15B
+1.64%+9.24%-11.30%-41.94% 27.93B
-0.44%-0.81%+60.77%-4.18% 25.27B
-1.20%+2.84%-6.22%+6.34% 20.84B
Average -0.26%+3.73%-1.43%+1.46% 53.68B
Weighted average by Cap. +0.24%+5.20%-3.69%+2.93%

Financials

2025 2026
Net sales 2.14M 1.87M 1.73M 1.6M 3.04M 203M 3.08M 20.69M 8.05M 100M 8.03M 7.86M 346M 2.04M 1.78M 1.64M 1.52M 2.89M 193M 2.94M 19.7M 7.66M 95.4M 7.65M 7.48M 330M
Net income -10.48M -9.17M -8.45M -7.84M -14.88M -995M -15.11M -101M -39.42M -491M -39.35M -38.5M -1.7B -8.23M -7.2M -6.64M -6.15M -11.68M -781M -11.87M -79.58M -30.95M -385M -30.9M -30.23M -1.33B
Net Debt -4.13M -3.61M -3.33M -3.08M -5.85M -392M -5.95M -39.89M -15.51M -193M -15.49M -15.15M -668M -4.33M -3.79M -3.49M -3.24M -6.14M -411M -6.24M -41.87M -16.28M -203M -16.25M -15.9M -701M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
26-07-07 US$3.030 -3.50% 15,947
26-07-06 US$3.140 +2.61% 21,713
26-07-02 US$3.060 -0.97% 11,386
26-07-01 US$3.090 -3.13% 24,053
26-06-30 US$3.190 -0.62% 11,765
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.030USD
Average target price
15.00USD
Spread / Average Target
+395.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock